Dual inhibition of PI3K and PARP demonstrates synergistic anti-tumor activity in endometrioid endometrial cancer patient derived xenografts

被引：0
|
作者：
Hall, Tracilyn [1 ]
DiGloria, Celeste [1 ]
Kim, Minji [1 ]
Zhang, Ling [1 ]
Foster, Rosemary [1 ]
Growdon, Whitfield [1 ]
Rueda, Bo [1 ]
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Cambridge, MA 02138 USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 136卷 / 02期
关键词：
D O I：
10.1016/j.ygyno.2014.11.033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：398 / 398
页数：1
相关论文
共 50 条
  • [41] SIMILAR PI3K AND RTK-RAS STATUS IN PATIENT DERIVED COLORECTAL CANCER-XENOGRAFTS AND PATIENTS
    Nunes, M.
    Weiswald, L. B.
    Vrignaud, P.
    Vacher, S.
    Turlotte, E.
    Richon, S.
    Roman-Roman, S.
    Bieche, I.
    Dangles-Marie, V.
    ANNALS OF ONCOLOGY, 2013, 24 : 31 - 31
  • [42] ANTI-TUMOR ACTIVITY OF DUAL PI3K/MTOR INHIBITORS PF-04691502 AND PF-05212384 IN GLIOBLASTOMA STEM-LIKE CELLS WITH DIFFERENTIAL PI3K PATHWAY ACTIVATION
    Tanaka, Shota
    Klofas, Lindsay K.
    Wakimoto, Hiroaki
    Borger, Darrell R.
    Iafrate, A. J.
    Batchelor, Tracy T.
    Chi, Andrew S.
    NEURO-ONCOLOGY, 2012, 14 : 26 - 26
  • [43] Combined Blockade of PI3K/AKT and EGFR/HER3 Enhances Anti-Tumor Activity in Triple Negative Breast Cancer
    Tao, J.
    Ip, P.
    Auricchio, N.
    Juric, D.
    Yu, M.
    Shyamala, M.
    Kim, P.
    Singh, S.
    Hazra, S.
    Haber, D.
    Scaltriti, M.
    Baselga, J.
    CANCER RESEARCH, 2012, 72
  • [44] Synergistic anti-tumor efficacy of the dual PI3K-δ/PI3K-γ inhibitor duvelisib with PD-1 blockade in solid tumor and lymphoma models
    Coma, Silvia
    Funk, Christopher R.
    Wang, Shuhua
    Waller, Edmund K.
    Weaver, David T.
    Pachter, Jonathan A.
    CANCER RESEARCH, 2020, 80 (16)
  • [45] Anti-Tumor Activity for Novel Dual PI3K/BET Inhibitors, SF2523 and SF1126, in Ewing Sarcoma
    Goldin, A. N.
    Singh, A. R.
    Muldong, M.
    Joshi, S.
    Jamieson, C.
    Durden, D. L.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S76 - S76
  • [46] Adaptive resistance of patient-derived ovarian cancer cells to PI3K/mTOR inhibition
    Zervantonakis, Ioannis
    Chen, Hsing-Yu
    Muranen, Taru
    Liu, Joyce
    Drapkin, Ronny
    Matulonis, Ursula
    Brugge, Joan
    CLINICAL CANCER RESEARCH, 2015, 21
  • [47] Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
    Migliardi, Giorgia
    Sassi, Francesco
    Torti, Davide
    Galimi, Francesco
    Zanella, Eugenia R.
    Buscarino, Michela
    Ribero, Dario
    Muratore, Andrea
    Massucco, Paolo
    Pisacane, Alberto
    Risio, Mauro
    Capussotti, Lorenzo
    Marsoni, Silvia
    Di Nicolantonio, Federica
    Bardelli, Alberto
    Comoglio, Paolo M.
    Trusolino, Livio
    Bertotti, Andrea
    CLINICAL CANCER RESEARCH, 2012, 18 (09) : 2515 - 2525
  • [48] Dual targeting of PI3K and mTOR results in synergistic growth inhibition in NSCLC cells
    Chao, Herta H.
    Zito, Christopher
    Jilaveanu, Lucia
    Anagnostou, Valsamo
    Rimm, David
    Bepler, Gerold
    Camp, Robert
    Kluger, Harriet M.
    CANCER RESEARCH, 2010, 70
  • [49] Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
    Elina Jokinen
    Niina Laurila
    Jussi P Koivunen
    BMC Cancer, 12
  • [50] Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
    Jokinen, Elina
    Laurila, Niina
    Koivunen, Jussi P.
    BMC CANCER, 2012, 12
12345